Skip to Content
Stock Analyst Update

No Changes to Healthcare Stocks Amid Coronavirus

We don't assume any significant long-term financial impact from the outbreak.

Mentioned: , , , ,

We're not making any changes to our fair value estimates within our healthcare coverage as a result of the novel coronavirus (2019-nCoV) outbreak. As scientists and physicians grapple with finding treatments or vaccines, investors have been eager to find firms that have the most promising technologies for containing the spread of the virus and helping currently infected patients recover. For example, shares of Gilead rose significantly on Monday as investors processed the news that the first confirmed U.S. case of 2019-nCoV appears to have responded to Gilead's investigational Ebola virus treatment remdesivir. 

However, with a placebo-controlled trial of remdesivir just beginning in China and other potentially generic treatment options also being tested, we're not making any changes to our Gilead fair value estimate at this time. Beyond Gilead, other names in our coverage--like Roche, whose diagnostics arm has a coronavirus assay available for research use but not yet approved--could see some tailwinds as need for diagnostics rises. Medical supplies (preventive products like masks and soaps and commodity hospital supplies like saline solutions) could also see increased short-term demand. However, we don't assume any significant long-term financial impact from the outbreak.

Unless 2019-nCoV has staying power, most of these sales tend to reverse in the following year, limiting the impact of any valuation effect. Additionally, most of the supplies used to prevent the spread of viruses tend to be commodity-like products, so there is more limited ability for firms to retain excess profits, especially over the long term.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Karen Andersen does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.